Gluten Challenge in Celiac Disease
1 other identifier
interventional
99
1 country
1
Brief Summary
Up till 30 participants with celiac disease on a glutenfree diet are asked to consume gluten containing cookies or bread for 3 days. Questionnaires and sampling of blood is done before, during and after.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2017
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 30, 2015
CompletedFirst Posted
Study publicly available on registry
June 8, 2015
CompletedStudy Start
First participant enrolled
April 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 13, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 13, 2025
CompletedJune 22, 2025
June 1, 2025
8.1 years
March 30, 2015
June 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Transcriptome of gluten-specific T cells
Transcriptional differences of glutenspecific vs. unspecific T cells
Day 6
Study Arms (1)
Participants
EXPERIMENTALParticipants are subjected to gluten intervention in an unblinded fashion.
Interventions
Challenge done in the form of a gluten containing cookie once daily, or up to four slices of regular bread daily.
Eligibility Criteria
You may qualify if:
- Celiac disease confirmed by biopsy
- Age 18 - 80 years
- Gluten free diet last 6 months
- Subject has received information and signed the informed consent form
You may not qualify if:
- Pregnant or breast feeding
- Probability of participant becoming pregnant (f.ex. by not using adequate sexual prevention by woman in fertile age)
- Drugs influencing immune system used last 3 months
- Current infectious disease of moderate or high severity
- Other chronic active intestinal disease
- Serious reaction on small amounts of gluten ingested
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Oslo University Hospitallead
- Stiftelsen Helse og Rehabiliteringcollaborator
- Helse Sor-Ostcollaborator
Study Sites (1)
Oslo university hospital - Rikshospitalet
Oslo, 0372, Norway
Related Publications (14)
Eggesbo LM, Risnes LF, Neumann RS, Lundin KEA, Christophersen A, Sollid LM. Single-cell TCR sequencing of gut intraepithelial gammadelta T cells reveals a vast and diverse repertoire in celiac disease. Mucosal Immunol. 2020 Mar;13(2):313-321. doi: 10.1038/s41385-019-0222-9. Epub 2019 Nov 14.
PMID: 31728027RESULTZuhlke S, Risnes LF, Dahal-Koirala S, Christophersen A, Sollid LM, Lundin KE. CD38 expression on gluten-specific T cells is a robust marker of gluten re-exposure in coeliac disease. United European Gastroenterol J. 2019 Dec;7(10):1337-1344. doi: 10.1177/2050640619874183. Epub 2019 Sep 7.
PMID: 31839959RESULTRisnes LF, Eggesbo LM, Zuhlke S, Dahal-Koirala S, Neumann RS, Lundin KEA, Christophersen A, Sollid LM. Circulating CD103+ gammadelta and CD8+ T cells are clonally shared with tissue-resident intraepithelial lymphocytes in celiac disease. Mucosal Immunol. 2021 Jul;14(4):842-851. doi: 10.1038/s41385-021-00385-8. Epub 2021 Mar 2.
PMID: 33654213RESULTDahal-Koirala S, Risnes LF, Neumann RS, Christophersen A, Lundin KEA, Sandve GK, Qiao SW, Sollid LM. Comprehensive Analysis of CDR3 Sequences in Gluten-Specific T-Cell Receptors Reveals a Dominant R-Motif and Several New Minor Motifs. Front Immunol. 2021 Apr 13;12:639672. doi: 10.3389/fimmu.2021.639672. eCollection 2021.
PMID: 33927715RESULTChristophersen A, Zuhlke S, Lund EG, Snir O, Dahal-Koirala S, Risnes LF, Jahnsen J, Lundin KEA, Sollid LM. Pathogenic T Cells in Celiac Disease Change Phenotype on Gluten Challenge: Implications for T-Cell-Directed Therapies. Adv Sci (Weinh). 2021 Nov;8(21):e2102778. doi: 10.1002/advs.202102778. Epub 2021 Sep 8.
PMID: 34495570RESULTChristophersen A, Zuhlke S, Lund EG, Snir O, Dahal-Koirala S, Risnes LF, Jahnsen J, Lundin KEA, Sollid LM. Pathogenic T Cells in Celiac Disease Change Phenotype on Gluten Challenge: Implications for T-Cell-Directed Therapies. Adv Sci (Weinh). 2022 Dec;9(34):e2205912. doi: 10.1002/advs.202205912. No abstract available.
PMID: 36482157RESULTStamnaes J, Stray D, Stensland M, Sarna VK, Nyman TA, Lundin KEA, Sollid LM. In Well-Treated Celiac Patients Low-Level Mucosal Inflammation Predicts Response to 14-day Gluten Challenge. Adv Sci (Weinh). 2021 Jan 4;8(4):2003526. doi: 10.1002/advs.202003526. eCollection 2021 Feb.
PMID: 33643806RESULTTye-Din JA, Skodje GI, Sarna VK, Dzuris JL, Russell AK, Goel G, Wang S, Goldstein KE, Williams LJ, Sollid LM, Lundin KE, Anderson RP. Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity. United European Gastroenterol J. 2020 Feb;8(1):108-118. doi: 10.1177/2050640619874173. Epub 2019 Sep 3.
PMID: 32213060RESULTGoel G, Tye-Din JA, Qiao SW, Russell AK, Mayassi T, Ciszewski C, Sarna VK, Wang S, Goldstein KE, Dzuris JL, Williams LJ, Xavier RJ, Lundin KEA, Jabri B, Sollid LM, Anderson RP. Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. Sci Adv. 2019 Aug 7;5(8):eaaw7756. doi: 10.1126/sciadv.aaw7756. eCollection 2019 Aug.
PMID: 31457091RESULTRisnes LF, Christophersen A, Dahal-Koirala S, Neumann RS, Sandve GK, Sarna VK, Lundin KE, Qiao SW, Sollid LM. Disease-driving CD4+ T cell clonotypes persist for decades in celiac disease. J Clin Invest. 2018 Jun 1;128(6):2642-2650. doi: 10.1172/JCI98819. Epub 2018 May 14.
PMID: 29757191RESULTDahal-Koirala S, Risnes LF, Christophersen A, Sarna VK, Lundin KE, Sollid LM, Qiao SW. TCR sequencing of single cells reactive to DQ2.5-glia-alpha2 and DQ2.5-glia-omega2 reveals clonal expansion and epitope-specific V-gene usage. Mucosal Immunol. 2016 May;9(3):587-96. doi: 10.1038/mi.2015.147. Epub 2016 Feb 3.
PMID: 26838051RESULTSkodje GI, Sarna VK, Minelle IH, Rolfsen KL, Muir JG, Gibson PR, Veierod MB, Henriksen C, Lundin KEA. Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity. Gastroenterology. 2018 Feb;154(3):529-539.e2. doi: 10.1053/j.gastro.2017.10.040. Epub 2017 Nov 2.
PMID: 29102613RESULTSarna VK, Skodje GI, Reims HM, Risnes LF, Dahal-Koirala S, Sollid LM, Lundin KEA. HLA-DQ:gluten tetramer test in blood gives better detection of coeliac patients than biopsy after 14-day gluten challenge. Gut. 2018 Sep;67(9):1606-1613. doi: 10.1136/gutjnl-2017-314461. Epub 2017 Aug 4.
PMID: 28779027RESULTHerfindal AM, Nilsen M, Aspholm TE, Schultz GIG, Valeur J, Rudi K, Thoresen M, Lundin KEA, Henriksen C, Bohn SK. Effects of fructan and gluten on gut microbiota in individuals with self-reported non-celiac gluten/wheat sensitivity-a randomised controlled crossover trial. BMC Med. 2024 Sep 4;22(1):358. doi: 10.1186/s12916-024-03562-1.
PMID: 39227818DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Knut EA Lundin, MD PhD
Oslo University Hospital and University of Oslo
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, M.D., PhD., Consultant gastroenterologist
Study Record Dates
First Submitted
March 30, 2015
First Posted
June 8, 2015
Study Start
April 1, 2017
Primary Completion
May 13, 2025
Study Completion
May 13, 2025
Last Updated
June 22, 2025
Record last verified: 2025-06